Tharimmune, inc. THAR.US Overview
THAR AI Analysis & Strategy
Analysis Conclusion
The stock has a lower value rating; if aiming for value investing, existing long-term positions might require gradual reduction.
THAR Current Performance
4.14%
Tharimmune, inc.
2.83%
Avg of Sector
-0.07%
S&P500
THAR Key Information
THAR Financial Forecast
Unit : USD
THAR Earnings Table
THAR Profile
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
Price of THAR
THAR FAQ
When is THAR's latest earnings report released?
The most recent financial report for Tharimmune, inc. (THAR) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating THAR’s short-term business performance and financial health. For the latest updates on THAR’s earnings releases, visit this page regularly.
How much cash does THAR have?
At the end of the period, Tharimmune, inc. (THAR) held Total Cash and Cash Equivalents of 1.08M, accounting for 0.65 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is THAR's EPS continuing to grow?
According to the past four quarterly reports, Tharimmune, inc. (THAR)’s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.99. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of THAR?
Tharimmune, inc. (THAR)’s Free Cash Flow (FCF) for the period is -2.69M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 4.82% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of THAR?
The latest valuation data shows Tharimmune, inc. (THAR) has a Price-To-Earnings (PE) ratio of -0.33 and a Price/Earnings-To-Growth (PEG) ratio of 0.01. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.